A1 Refereed original research article in a scientific journal
Treatment of congenital hypothyroidism - impact of secular changes in levothyroxine initial dose on early growth
Authors: Niuro Laura, Danner Emmi, Viikari Liisa, Kero Jukka, Huopio Hanna, Jääskeläinen Jarmo, Niinikoski Harri
Publisher: KARGER
Publication year: 2022
Journal: Hormone Research in Paediatrics
Journal name in source: HORMONE RESEARCH IN PAEDIATRICS
Journal acronym: HORM RES PAEDIAT
Number of pages: 16
ISSN: 1663-2818
eISSN: 1663-2826
DOI: https://doi.org/10.1159/000528567(external)
Web address : chttps://doi.org/10.1159/000528567
Self-archived copy’s web address: https://research.utu.fi/converis/portal/detail/Publication/178226467(external)
Introduction: Newborn screening of congenital hypothyroidism (CH) has enabled early treatment with levothyroxine (LT4), ensuring normal growth and development. The initial LT4 dose recommendation has increased over decades. We evaluated whether the increased LT4 dosing influenced thyroid-stimulating hormone (TSH) and thyroxine (fT4) concentrations, growth, or treatment-related symptoms.
Methods: LT4 doses, TSH, fT4, anthropometrics, and treatment-related symptoms until age two years were evaluated in 172 Finnish CH patients born between 1980 and 2018. The patients were grouped according to birth decade: 1980s (n = 19, mean LT4 starting dose 6.8 μg/kg/day), 1990s (n = 50, 7.4 μg/kg/day), 2000s (n = 59, 9.7 μg/kg/day) and 2010s (n = 44, 10.8 μg/kg/day)
Results: TSH concentrations were higher during the first two years of life in children born in 1980s compared to children born later. TSH concentrations were often subnormal in children receiving higher LT4 doses (children born in 2000s and 2010s). However, symptoms of overtreatment were uncommon. Linear or head growth showed no differences between the groups during the first two years of life. Although growth was within the normal spectrum, children in all groups were shorter than their target length at two years and their weight-for-length was above the mean through the first two years of life.
Discussion/Conclusion: Current treatment practice with higher LT4 dose normalizes TSH rapidly without significant increase in side effects. However, irrespective of initial LT4 dose, children were shorter than expected at 2 years of age. Effects of different initial LT4 dose on cognitive development urges further investigation.
Downloadable publication This is an electronic reprint of the original article. |